N@N

Vitro CEO Interviews with Wall Street Reporter Regarding New Stem Cell Tools for Cellular Medicine

_{//health-fitness.news-articles.net/content/2010/ .. g-new-stem-cell-tools-for-cellular-medicine.html}
^{Published in Health and Fitness on Thursday, May 20th 2010 at 6:36 GMT by Market Wire}  

GOLDEN, Colo.--([ BUSINESS WIRE ])--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced that its CEO, Dr. James Musick was interviewed regarding the Companya™s current results and future prospects. The interview may be accessed through the following link: [ http://www.wallstreetreporter.com/2010/05/vitro-diagnostics-inc-otc-bb-vodg/ ].

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are identified by words such as aintends,a aanticipates,a abelieves,a aexpectsa and ahopesa and include, without limitation, statements regarding the Companya™s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Companya™s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Companya™s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.